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Abstract
Cytoreductive nephrectomy has been an integral part of management in metastatic renal cell carcinoma for patients with good performance status, 
based on the benefit shown by prospective trials in the interferon era and retrospective trials in the targeted therapies era. Clinical Trial to Assess the 
Importance of  Nephrectomy (CARMENA), the first prospective phase III trial comparing a targeted agent alone (sunitinib) versus nephrectomy plus 
sunitinib, has been recently published, showing non-inferiority for the nephrectomy-sparing arm. In this article, we discuss the impact of nephrectomy 
including its immune-mediated effects, surgical morbidity and mortality, and the clinical data supporting the indications of nephrectomy in order to 
analyze the CARMENA trial in context, with the aim to identify optimal strategies for different patient populations in the metastatic setting.
Keywords: cytoreductive nephrectomy; immunotherapy; metastatic renal cell carcinoma; sunitinib; surgical outlook
Received: 08 January 2019; Accepted after revision: 28 January 2019; Published: 05 March 2019
Author for Correspondence: Mauricio Burotto, Oncology Department, Los Andes University,  Bradford Hill Clinical Research Center, Santiago, 
Chile. Email: mauricioburotto@gmail.com
How to cite: Renner A et al. Is cytoreductive nephrectomy still a standard of care in metastatic renal cell carcinoma? J Kidney Cancer VHL 
2019;6(1): 1–7.
Doi: http://dx.doi.org/10.15586/jkcvhl.2019.114
Copyright: Renner A et al.
License: This open access article is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). http://creativecommons.org/ 
licenses/by/4.0
Introduction
Kidney cancer is the ninth most common cancer in men and 
the 14th in women, with an estimated 338,000 new cases 
worldwide each year; it is also the 16th most common cause 
of death from cancer, causing 143,000 deaths in 2012  (1). 
Renal cell carcinoma (RCC) accounts for approximately 
90% of all kidney malignancies; the most common histo-
logical type being clear cell carcinoma, which is present in 
80–90% of cases. Median age at diagnosis is 64 years, and 
5-year survival rates have been steadily increasing over time, 
from 50.1% in 1977 to 74.4% in 2014, mainly reflecting stage 
migration to earlier tumors diagnosed incidentally through 
image tests. This 5-year survival goes down to just 11.6% for 
metastatic disease according to the US Surveillance Epidemi-
ology and End Results (SEER) database (2).
The only known curative therapy for RCC localized within 
the kidney is complete surgical resection of  the tumor, via 
radical or partial nephrectomy. At diagnosis, up to 30% 
of patients present with metastatic renal cell carcinoma 
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(mRCC)  (3). In  the metastatic setting, cytoreductive ne-
phrectomy (CN) has been a standard of  care for fit patients 
since randomized controlled trials in the interferon era (4, 
5) showed an overall survival (OS) benefit for patients un-
dergoing nephrectomy followed by systemic treatment ver-
sus systemic therapy alone. However, systemic therapy for 
mRCC has changed significantly in the last 15 years, with 
several new active agents available. Thus, the role and timing 
of  nephrectomy has been questioned, given the surgical risks 
and potential delays in systemic treatment (6). The evidence 
for CN in the targeted therapy era was, until recently, based 
purely on retrospective studies which have suggested that the 
OS benefit still exists.
Since new data from prospective SURTIME and CAR-
MENA trials are available, we believe it is an appropriate 
time to reassess this subject and try to define which patients 
may or may not benefit from CN in the mRCC setting with 
currently available therapies.
Biological Effects of Nephrectomy
Even though CN proved beneficial in prospective trials in the 
interferon era, the mechanism for the observed benefit is still 
not completely understood. Several studies have pointed to 
the immunologic dysfunction present in mRCC, which could 
be mitigated by removal of the primary tumor.
Lahn et al. (7) describe the significant elevation of 
 circulating proinflammatory and T-cell inhibitory cytok-
ines such as interleukins 6, 8 and 10 and TNF-α. Uzzo (8) 
 indicates that FasL expression by the tumor may be respon-
sible for the increased T-cell apoptosis seen in these patients. 
 Natural killer cell dysfunction mediated by regulation of the 
TGF-β/SMAD pathway to evade innate immune surveillance 
has been recently described (9). Dadian (10) measured pe-
ripheral immunological parameters pre- and post-nephrec-
tomy, showing a decreased inflammatory response, improved 
natural killer activity and increased immune activation after 
surgery. Also, inflammation and immune evasion mediated 
by elevated secretion of CCL1 by the tumor and increased 
presence of CCR8 (+) myeloid cells in peripheral blood and 
cancer tissues have been shown by Eruslanov (11). Ongoing 
trials such as NCT02446860 (12) are measuring changes in 
immune markers before and after neoadjuvant PD-1 block-
ade followed by nephrectomy and are trying to correlate 
them to both response and toxicity.
Besides the potential immunologically mediated effects of 
nephrectomy, Gatenby (13) proposed that metabolic acidosis 
associated with mild renal failure after unilateral nephrec-
tomy can decrease tumor growth and invasion.  Regarding 
the impact of nephrectomy on response rates to systemic 
treatment, the Flanigan et al. trial (4) which compared 
interferon plus CN versus CN alone showed that response 
rates to interferon remained at a very low  3.3 and 3.6% 
respectively. On  the first-line nivolumab plus ipilimumab 
versus sunitinib trial (14), 660 out of 859  patients (76.8%) 
underwent CN; here, the subgroup analysis shows that 
the  Hazard Ratio (HR) for death was 0.69  (0.53–0.89) in 
those who underwent nephrectomy and 0.63 (0.42–0.94) in 
those with no  nephrectomy, showing the benefit from immu-
notherapy does not appear to differ between these subgroups.
Surgical Outlook
Nephrectomy, as with most oncologic surgical procedures, 
aims to achieve removal of  gross tumor burden to increase 
survival and reduce symptoms. Before the era of  early im-
munotherapy, nephrectomy in the mRCC setting was mostly 
reserved for patients with only one metastatic lesion, and to 
control cancer-related symptoms such as hematuria, flank 
pain, and paraneoplastic syndrome (15, 16). As we moved 
into the interferon era, the use of  CN increased significantly, 
owing to the improved OS shown in prospective trials. In a 
SEER registry analysis, Conti et al. (17) reported that the 
proportion of  patients undergoing CN in the metastatic 
setting increased from 29% in 1993 to 39% in 2004; after 
that year (and coinciding with the introduction of  targeted 
therapies), a slight but progressive decrease was observed, 
less than 34% by 2010.
Regarding complications, CN can be a challenging pro-
cedure, with potential morbidity and mortality. Silberstein 
et al. (18) analyzed 195 mRCC patients who underwent 
nephrectomy at Memorial Sloan-Kettering Cancer Center 
(MSKCC) between 1989 and 2009, reporting that 27% of 
them developed grade ≥ 2 and 8% grade ≥ 3 complications 
within 8 weeks of  surgery; those who had complications 
were significantly less likely to receive systemic therapy 
within 56 days (OR 0.32; P = 0.024), and the best predic-
tors for postoperative complications were Karnofsky Per-
formance Scale (KPS) and age, even more so than other 
performance measures like MSKCC risk categories. Abdol-
lah et al. (19) reviewed results on 1063 patients undergo-
ing CN and found that in-hospital mortality was 2.4% and 
complications were present in 26.5% of  cases. Wallis et al. 
(20) reported a 3.2% mortality rate in a prospective registry 
in the USA. Using the SEER database, Cloutier et al. (21) 
demonstrated a 30-day mortality of  4.2% in mRCC patients 
(all T stages) compared with just 0.3% for T1-2N0M0 and 
1.3% for T3-4N0-2M0 disease; mortality reached 10.5% in 
the subset of  patients aged 80 years or older. Similarly, Sun 
et al. (22) confirmed that elderly patients (>75 years) were 
2.2-fold more likely to experience perioperative mortality 
than younger patients. You et al. (23) showed that in pa-
tients with two or more risk factors (KPS < 80, hemoglobin 
less than the lower limit of  normal, neutrophils greater than 
the upper limit of  normal, and clinical N2 stage), overall 
survival was not modified by CN. As we can see, patient se-
lection is critical in order to differentiate patients who may 
benefit from those who may not.
Cytoreductive nephrectomy for metastatic renal cell carcinoma
Journal of Kidney Cancer and VHL 2019; 6(1): 1–7 3
Evidence for Cytoreductive Nephrectomy 
in the Interferon Era
With the emergence of  interferon (IFN) and interleukin-2 
(IL-2) immunotherapy, the role of  CN was reevaluated in 
two prospective randomized trials. The SWOG 8949 trial 
by Flanigan et al. (4) evaluated overall survival in 241 treat-
ment-naïve patients, who were randomized to either ne-
phrectomy followed by IFN or IFN alone; the groups were 
imbalanced, with more ECOG PS 0 patients in the surgery 
arm, which by itself  may have accounted for their better 
survival. Median overall survival (mOS) was 11.1 versus 
8.1 months favoring the surgery plus interferon arm, with 
overlapping confidence intervals and a borderline P-value 
(P = 0.05). Another prospective trial was EORTC 30947 by 
Mickisch et al. (5) which compared 42 patients undergoing 
surgery plus IFN versus 43 patients who received IFN alone, 
showing an OS of 17 versus 7 months, respectively (P = 0.03, 
HR 0.54, 95% CI 0.31–0.94).
Since EORTC 30947 and SWOG 8949 had identical pro-
tocols, a combined analysis was later published (6) including 
all 324 patients. The PS imbalance remained (PS 0 = 53.4% in 
the surgery + IFN arm versus 41.1% in the IFN alone arm), 
otherwise both arms were well balanced. Twelve percent of 
patients randomized to nephrectomy and IFN did not un-
dergo surgery and another 5.6% in this arm did not receive 
IFN, but they were all included in the intention to treat anal-
ysis. Median OS was 13.6 months for nephrectomy plus IFN 
versus 7.8 months for interferon alone (HR 0.69, 95% CI 
0.55–0.87, P = 0.002). The OS benefit was present in both 
PS 0 and 1 patients, but more pronounced for those in PS 0. 
Objective response rates (ORR) were low and did not differ 
between both arms: 6.9% in the nephrectomy plus IFN group 
versus 5.7% in the IFN alone group (P = 0.60). Surgical com-
plications were present in 23.4% of patients that underwent 
nephrectomy, including two surgical deaths (1.4%).
Once these data became available, nephrectomy became 
standard of care for patients with mRCC and PS 0-1. This 
was further supported by retrospective analyses showing 
nephrectomy as one of the several prognostic factors associ-
ated with improved OS. Motzer (24) performed a retrospec-
tive study on 670 patients with advanced RCC treated in 24 
successive clinical trials during 21 years at the MSKCC. Out 
of the six parameters identified as risk factors in the mul-
tivariate analysis, “absence of nephrectomy” had the least 
powerful association, but it was still significant, with a risk 
ratio of 1.35 for death (CI 95%, 1.13–1.61, P = 0.01).
Evidence for Cytoreductive Nephrectomy in the 
Targeted Therapies Era: Retrospective Data
In the last 15 years, there has been an explosive growth in the 
available systemic therapies for the management of mRCC, 
owing to the better understanding of molecular mechanisms 
involved in the development of renal cancer. Several agents 
targeting the vascular endothelial growth factor (VEGF) 
such as sunitinib (3), pazopanib (25), and bevacizumab (26) 
have proven to be effective in randomized trials. Mammalian 
target of rapamycin (mTOR) inhibitor temsirolimus has also 
shown superiority over IFN in patients with poor prognosis 
(27). More recently, drugs targeting the immune checkpoint 
inhibitor programmed death 1 receptor (PD-1) and its ligand 
(PDL-1) have also shown significant activity in RCC, alone 
or in combination with other agents (14). In pivotal trials for 
all these novel drugs, CN was performed in over 80% of pa-
tients, thus no analysis on the effect of surgery can be made 
based on their results.
Since effective therapy became available, delaying treat-
ment to perform a nephrectomy has become a concern. 
Several large retrospective studies have reviewed the effect 
of nephrectomy for patients treated with modern targeted 
 therapies, which are summarized in Table 1. Hanna et al. (28) 
evaluated data from the USA National Cancer Database be-
tween 2006 and 2013 in which nephrectomy was performed 
in 35% of mRCC patients analyzed (5374 out of 15,390). Pa-
tients were more likely to undergo nephrectomy if  they were 
younger, had lower tumor stage or N0 disease, were privately 
insured, or treated at an academic center. After adjusting for 
available covariates, patients who underwent nephrectomy 
had a lower risk of death (HR 0.45; 95% CI 0.40–0.50; P < 
0.001). It is interesting to note that they also report on the 
timing of surgery for 4223 patients (88.4% had nephrectomy 
before and 11.6% after targeted therapy): the 1-, 2-, and 
3-year OS rates were lower for those who had nephrectomy 
before targeted therapy (61.2%, 37.8%, and 26.6%) versus 
those who had nephrectomy after targeted therapy (73.3%, 
48.1%, and 35.3%) (P < 0.01).Heng (29) reviewed retrospec-
tive data from 1658 patients from nine countries with syn-
chronous mRCC treated with targeted therapies, comparing 
results for those who underwent nephrectomy (982) versus 
those who did not (676). There were significant imbalances in 
patient characteristics—those undergoing nephrectomy had 
better performance status and better International mRCC 
Database Consortium (IMDC) prognostic profiles. After ad-
justments for IMDC scores, HR for death was 0.60 (95% CI 
0.52–0.69; P < 0.0001) and median OS was 20.6 versus 9.6 
months benefiting the nephrectomy group. Conti et al. (17) 
reported survival outcomes for mRCC CN between 1993 and 
2010 in the SEER database. Nephrectomy was performed 
in 34% (6915 out of 20,104) of the patients. Neither PS nor 
several other known mRCC prognostic factors were available 
and thus they were not considered for statistical matching in 
this study. Age, tumor size, sex, ethnicity, region, and other 
factors differed between groups, and these were adjusted for 
in their analysis. Relative mortality HR was 0.43 (95% CI 
0.42–0.46, P < 0.05) favoring the CN arm. Abern (30) also 
reviewed the SEER database between 2005 and 2009, where 
2629 out of 7143 patients (37%) underwent CN. Once again, 
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patient characteristics differed significantly—patients under-
going CN were younger and more likely to be white, male, 
and married. In this series, patients that underwent CN had 
improved 1-year survival (61% vs. 22%), and surgery was as-
sociated with improved overall survival (HR = 0.40, 95% CI 
0.37–0.43) on multivariable analysis.
Cytoreductive Nephrectomy in the Targeted 
Therapies Era: Prospective Data
The SURTIME trial (EORTC 30073) (31) was designed to 
compare two different strategies, both of which included ne-
phrectomy: the traditional approach of upfront CN followed 
by targeted therapy (sunitinib) versus upfront sunitinib with 
delayed CN after three cycles. So even though the SURTIME 
trial does not intend to answer the question whether we still 
need CN in mRCC, it sheds light on the best timing to per-
form it. Arms were well balanced between immediate and de-
ferred surgery; median age was 60 and 58 years, respectively; 
MSKCC intermediate risk was reported for 86% versus 87.7% 
of patients; WHO PS 0 accounted for 72% versus 63.3% of 
patients; and mean primary tumor size was 93.1 mm versus 
96.8 mm. Trial results showed equivalent progression-free 
rate (PFR) at 28 weeks: 42.0% (95% CI 28.2–56.8) and 42.9% 
(28.8–57.8) in the immediate and deferred arms, respectively 
(P  >  0.99). The OS analysis favored deferred versus immedi-
ate CN with HR 0.57 (95% CI 0.34–0.95, P  =  0.032) and a 
twofold median OS advantage: 32.4 (95% CI 14.5–65.3) and 
15.1 months (95% CI 9.3–29.5), respectively. Surgical com-
plications occurred less frequently in the deferred CN arm 
(27.5%) compared to the upfront CN arm (43.5%).
The Clinical Trial to Assess the Importance of Nephrec-
tomy (CARMENA) (32) is by far the largest trial in this 
setting, and the only one to include TKIs. It is a prospec-
tive, randomized, open-label, non-inferiority trial where 450 
mRCC patients were randomized in a 1:1 ratio to undergo ne-
phrectomy followed by sunitinib or to be administered suni-
tinib alone. Eligible patients had to be suitable candidates for 
nephrectomy— >18 years of age, Eastern  Cooperative Oncol-
ogy Group (ECOG) performance status score 0 or 1, absent 
or treated brain metastases, and acceptable organ function. 
Randomization was stratified according to MSKCC prognos-
tic groups, identified as intermediate (55.6%) and poor risk 
(44.6%) in the nephrectomy plus sunitinib arm versus inter-
mediate (58.5%) and poor risk (41.5%) in the sunitinib alone 
arm. Median primary tumor size was 86 mm for the suni-
tinib arm and 88 mm for the surgery arm. Median number 
of metastatic sites was 2 (range 1–5) for both arms. Sunitinib 
50 mg was administered in a 4 weeks on/2 weeks off  schedule. 
Median OS, which was the primary endpoint of the study, 
was 18.4 months for sunitinib alone versus 13.9 months in 
the sunitinib plus nephrectomy group; HR for death was 0.89 
(95% CI 0.71–1.10; upper boundary of the 95% confidence 
interval for noninferiority ≤ 1.20). In an exploratory analy-
sis, the MSKCC intermediate risk subgroup median OS was 
19.0 months with CN plus sunitinib and 23.4 months with 
sunitinib alone (HR = 0.92; 95% CI 0.60–1.24); in the case 
of MSKCC poor-risk patients, it was 10.2 and 13.3 months, 
respectively (HR = 0.86; 95% CI 0.62–1.17). No significant 
differences in ORR or progression-free survival (PFS) were 
observed. Median duration of sunitinib treatment was longer 
in the sunitinib-alone arm (8.5 vs 6.7 months, P = 0.04), and 
Table 1. Large (>1.000 patients) retrospective cohort studies evaluating the effect of cytoreductive nephrectomy on overall 
 survival in mRCC.
Reference 
(year)
Participants 
(n)
Treatment  
arms (n)
Median 
age (years)
Poor PS (KPS > 80 
or ECOG ≥ 2)
Poor patient risk 
category (IMDC 
or MSKCC)
Clinical 
stage T1
mOS 
(months)
Hanna et al. 
(2016) (28)
15,390 CN (5374) 60 NR NR 29.5% 32.5
No CN (10,016) 64 NR NR 15.3% 14.9
Heng et al. 
(2014) (29)
1658 CN (982) 60 19% 28% NR 20.6
No CN (676) 59 42% 54% NR 9.6
Conti et al. 
(2014) (17)
20,104 CN (6915) 61 NR NR NR 15
No CN (13,189) 68 NR NR NR 4
Abern et al. 
(2014) (30)
7143 CN (2629) 61 NR NR 15% NR
No CN (4514) 68 NR NR 19% NR
Statistically significant differences in bold.
NR, not reported; CN, cytoreductive nephrectomy; PS, performance status; MSKCC, Memorial Sloan Kettering Cancer Center; mOS, median 
overall survival; KPS, Karnofsky Performance Scale; ECOG, Eastern Cooperative Oncology Group; IMDC, International mRCC Database 
Consortium.
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dose reductions were equally frequent in both arms (30.6% vs 
30.5%, respectively). An overview of these prospective trials 
is summarized in Table 2.
Benefit Discrepancy between Retrospective and 
Prospective Data in the Post-Interferon Era
The available retrospective studies we discussed previously 
consistently show an overall survival advantage for the com-
bination approach with upfront CN followed by targeted 
therapy, which contrasts with the prospective CARMENA 
trial showing that targeted therapy alone is non-inferior for 
OS compared to the combination of CN followed by targeted 
therapy, and also the SURTIME trial which shows that de-
layed nephrectomy has similar PFR and a possible OS ad-
vantage compared to immediate CN. This could be explained 
by several factors.
Retrospective trials in this setting are prone to patient se-
lection bias, as all the trials we discussed show that patients 
selected for surgery were usually younger, had better perfor-
mance status and had better prognostic scores. All publica-
tions tried to address this by adjusting for prognostic factors; 
however, these adjustments were limited to what was collected 
and available in the source database, so this bias was not fully 
accounted for in any of the reviewed studies. Another signifi-
cant difference is that both prospective trials included only pa-
tients with good performance status (PS 0-1), as most patients 
in PS 2 or more would not be candidates for surgery in the 
real-world setting; retrospective trials did not have the same 
criteria. There is also the possibility of publication bias, with 
negative results for nephrectomy series less likely to be pub-
lished in peer-reviewed journals. It is also important to note 
that three out the four discussed retrospective series analyzed 
the same SEER registry (although with differing time frames 
and  criteria), and thus, similar results were to be expected.
Regarding prospective trials, SURTIME did not reach its 
initial accrual objective, and after 5.7 years, it included just 
99 patients from 19 institutions; given the poor accrual, it 
was decided to report the PFR at week 28 as the primary 
endpoint, which required 98 patients, instead of the original 
median PFS, which required 380 events to detect a 3-month 
increase. That means, the study, although positive for its 
PFR primary objective, was underpowered for the OS analy-
sis, and the advantage seen in the delayed nephrectomy arm 
should be taken as an exploratory analysis.
The CARMENA trial also accrued slowly, taking 8 years to 
complete. It included a high percentage of poor-risk patients 
(44 and 41% in the CN plus sunitinib and sunitinib-alone 
arms, respectively); retrospective data have suggested that 
poor-risk patients derive limited or no benefit from CN,34 but 
given these were good PS patients with high tumor burden, 
it is still clinically relevant. Patients in the nephrectomy-suni-
tinib arm also had a higher rate of T3/T4 disease than those 
in the sunitinib arm: 70.1% versus 51%, although median pri-
mary tumor size was similar. It is also important to note that 
a significant number of patients (17%) in the sunitinib-only 
arm underwent nephrectomy because of acute symptoms or 
incomplete response.
Future Landscape
Both prospective trials with targeted therapies that we have 
reviewed used sunitinib as upfront systemic therapy, which 
mirror current clinical practice as anti-VEGF TKIs have 
been the mainstay in the first-line setting the last 10 years 
(33). This scenario is changing, moving towards immunother-
apy-based combinations. In the pivotal CheckMate 214 trial 
(14), nivolumab plus ipilimumab showed superior OS com-
pared to sunitinib in the first–line setting; this combination 
was approved by the FDA in April 2018 for IMDC interme-
diate- and poor-risk patients. In the phase III IMmotion 151 
trial (34), atezolizumab plus bevacizumab showed superior 
PFS compared to sunitinib, with OS data still immature at 
the first interim analysis. Another combination showing great 
Table 2. Prospective trials comparing nephrectomy followed by systemic therapy versus systemic therapy alone in mRCC.
Reference (year)
Participants 
(n)
Treatment 
arms
Median 
age (years)
ECOG PS 0–1 (%)
Patient risk 
(MSKCC)
ORR 
(%)
mOS 
(months)
Méjean et al. (2018) (32) 450 CN + 
Sunitinib
63 0 (57.5%) 1 (42.5%) Inter (55.6%) 27.4% 13.9
Sunitinib 62 0 (54.5%) 1 (45.5%) Poor (44.4%) 29.1% 18.4
Flanigan et al. (2001) (4) 120 CN + IFNa 59 0 (48%) 1 (52%) Not available 3.3% 11.1
IFNa 59 0 (40%) 1 (60%) Not available 3.6% 8.1
Mickisch et al. (2001) (5) 85 CN + IFNa 61 0 (55%) 1 (45%) Not available 19% 17
IFNa 56 0 (42%) 1 (58%) Not available 12% 7
NR, not reported; CN, cytoreductive nephrectomy; PS, performance status; IFNa, interferon alpha; MSKCC, Memorial Sloan Kettering Cancer 
Center; ORR, objective response rate; mOS, median overall survival; ECOG, Eastern Cooperative Oncology Group.
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activity on earlier phases is pembrolizumab plus axitinib, as 
reported by Atkins et al. (35) in open-label phase Ib trial in 
52 mRCC patients: ORR was 73% and median PFS was 20.9 
months. As these therapies eventually move into the clinical 
practice, we will need to reevaluate the role of CN.
Conclusions
The advances in management of mRCC since 2005 have been 
rapid, and standards of care are changing, with several new 
effective treatment options available. In this scenario, and 
given the new evidence available, CN still plays an import-
ant role in the management of mRCC, despite the morbidity 
and mortality associated with the procedure. We believe most 
patients with low metastatic burden and good performance 
status should be offered CN, while patients with poor PS and 
advanced age will probably not benefit from surgery. In that 
advanced age scenario, systemic therapy alone could be an 
option, especially if  tumor burden is high, whether if  it´s low, 
observation would be our first alternative. As for patients with 
good PS and high tumor burden, the CARMENA trial pro-
vides the best currently available evidence, and we should act 
accordingly: upfront CN should not be considered standard 
of care, but careful consideration of not only disease-specific 
risk scores but also surgical risk, resectability, morbidity, and 
the patient’s personal preference must be taken into account 
in the decision-making process.
The rapid advances in the field are unlikely to slow any 
time soon, with sunitinib being increasingly challenged by 
newer agents and immunotherapy-based combinations in the 
first-line setting. Whether CN continues to play a role in the 
future will need to be evaluated prospectively.
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